Novo Nordisk posts Q1 growth, weaker EPS

Novo Nordisk just gave investors the classic GLP-1 earnings headache — huge demand, messy economics. The company’s first-quarter 2026 numbers looked great at first glance, with reported sales up 32% at constant exchange rates. But that headline was flattered by a big one-off reversal tied to the U.S. 340B drug-pricing program. Strip that out, and the quarter becomes a lot more interesting: demand is booming, but price is slipping. ### Why did the quarter look so strong? Because the reported figures included a non-recurring boost. Novo said reported sales rose to DKK 96.8 billion and reported operating profit jumped 65%, helped by that 340B provision reversal in the U.S. That made the top line and margin line look much healthier than the underlying business really was. (biospace.com) ### What did the underlying business actually do? Once you back out the one-time item, adjusted sales fell 4% at constant exchange rates and adjusted operating profit fell 6%. Novo was blunt about the reason — lower realized prices, partly offset by GLP-1 volume growth across geographies. That is the whole story in one sentence: more units, worse pricing. (cnbc.com) ### Where was the volume coming from? Mostly Wegovy. Novo’s obesity business still grew on an adjusted basis, with obesity-care sales up 22% at constant exchange rates. The new oral Wegovy launch in the U.S. was especially strong. Novo said the pill generated DKK 2.256 billion in first-quarter sales, reached about 1.3 million prescriptions in the quarter, and crossed 200,000 weekly prescriptions by the week ending April 17. Management called it the strongest-ever GLP-1 volume launch in the U.S. (biospace.com) ### So where is the pressure coming from? The U.S. market. Novo said U.S. adjusted sales fell 11% in the quarter because lower realized prices more than offset volume growth across the Wegovy portfolio. Basically, Novo is still selling a lot more drug, but it is getting paid less per prescription after rebates, contracting, and payer mix. That is why a business can look operationally hot and financially cooler at the same time. (biospace.com) ### Why does the new Wegovy data matter then? Because efficacy is part of the pricing and market-share fight. On May 12, Novo presented new analyses showing that “early responders” on the higher 7.2 mg dose of Wegovy lost 27.7% of body weight on average at 72 weeks. Overall average weight loss on that higher dose was almost 21%. Novo launched the 7.2 mg shot in the U.S. about a month earlier, and three large pharmacy benefit managers had already added it to standard formularies. (biospace.com) ### Is this about Eli Lilly? A lot of it is. Eli Lilly’s Zepbound has been the tougher efficacy benchmark in obesity, and Novo is trying to narrow that gap with higher-dose Wegovy and with oral semaglutide. Better weight-loss data can help with doctors and payers, but the catch is that stronger clinical data does not automatically fix rebate pressure. Novo can win more prescriptions and still feel margin strain if the net price keeps sliding. (cnbc.com) ### Did management still raise guidance? Yes — and that is why the market did not read this as a broken story. Novo raised its 2026 outlook, citing higher expectations for GLP-1 sales. But even the updated guide still points to adjusted sales and adjusted operating profit declining 4% to 12% for the year, excluding the 340B reversal. So management is saying demand is better than expected, while also admitting the price environment is still rough. (cnbc.com) ### What is the real takeaway? Novo Nordisk is not dealing with a demand problem. It is dealing with a monetization problem. The business is moving a lot of Wegovy — especially the new pill — and it now has fresh high-dose data to support the brand. But until price, mix, and rebates stabilize in the U.S., every “great quarter” is going to need an asterisk. (biospace.com) (cnbc.com)